Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Aug;19(6):195-201.
doi: 10.1016/j.tcm.2009.12.003.

Discovery and validation of new molecular targets in treating dyslipidemia: the role of human genetics

Amit V Khera  1 , Daniel J Rader
Affiliations
Review

Discovery and validation of new molecular targets in treating dyslipidemia: the role of human genetics

Amit V Khera et al. Trends Cardiovasc Med. 2009 Aug.

Abstract

Several high-profile failures of lipid-related therapeutics in clinical trials have led to intense interest in improved discovery and preclinical prioritization of potential targets. The careful study of patients with rare monogenic disorders has played a key role in establishing the causal role of cholesterol in atherosclerosis and highlighting viable drug targets. Systematic efforts to extend the association of common variants linked with lipid levels to coronary disease enable assessment of the vascular consequences of lifelong differences in lipids due to variation in specific molecules. This application of genetic epidemiology, termed Mendelian randomization, may prove useful in informing ongoing drug development efforts.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Selected applications of Mendelian randomization
Mendelian randomization analyses require robust associations between 1) a genetic variant and an intermediate phenotype; and 2) the intermediate phenotype and disease. If this relationship is causal, the genetic variant should related to disease as well. This evidence for causality has been confirmed for variants affecting both LDL and Lipoprotein(a) levels (A and B), but not C-reactive protein (CRP) (C).
See this image and copyright information in PMC

References

    1. Smith GD, Timpson N, Ebrahim S. Strengthening causal inference in cardiovascular epidemiology through Mendelian randomization. Ann Med. 2008;40:524–541. - PubMed
    1. Abifadel M, Varret M, Rabès JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34:154–156. - PubMed
    1. Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007a;357:1301–1310. - PubMed
    1. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007b;357:2109–2122. - PubMed
    1. Benlian P, De Gennes JL, Foubert L, et al. Premature atherosclerosis in patients with familial chylomicronemia caused by mutations in the lipoprotein lipase gene. N Engl J Med. 1996;335:848–54. - PubMed

Publication types

MeSH terms